NovaBay Pharmaceuticals Stock Price, News & Analysis (NYSEAMERICAN:NBY)

$3.45 -0.08 (-2.27 %)
(As of 02/22/2018 06:00 AM ET)
Previous Close$3.53
Today's Range$3.45 - $3.55
52-Week Range$2.25 - $5.00
Volume16,013 shs
Average Volume12,346 shs
Market Capitalization$54.92 million
P/E Ratio-5.52
Dividend YieldN/A
Beta-0.85

About NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals logoNovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.

Receive NBY News and Ratings via Email

Sign-up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNYSEAMERICAN:NBY
CUSIPN/A
Phone+1-510-8998800

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-5.515625
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.64)
Net IncomeN/A
Net Margins-59.81%
Return on Equity-389.40%
Return on Assets-84.88%

Miscellaneous

EmployeesN/A
Outstanding Shares15,390,000

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?

Shares of NovaBay Pharmaceuticals reverse split on the morning of Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) issued its quarterly earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.09. The biopharmaceutical company had revenue of $4.09 million for the quarter, compared to analyst estimates of $4.69 million. NovaBay Pharmaceuticals had a negative net margin of 59.81% and a negative return on equity of 389.40%. View NovaBay Pharmaceuticals' Earnings History.

Where is NovaBay Pharmaceuticals' stock going? Where will NovaBay Pharmaceuticals' stock price be in 2018?

4 brokerages have issued 12 month price targets for NovaBay Pharmaceuticals' stock. Their forecasts range from $5.00 to $8.00. On average, they expect NovaBay Pharmaceuticals' share price to reach $6.33 in the next twelve months. View Analyst Ratings for NovaBay Pharmaceuticals.

What are Wall Street analysts saying about NovaBay Pharmaceuticals stock?

Here are some recent quotes from research analysts about NovaBay Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus. " (2/15/2018)
  • 2. Maxim Group analysts commented, "NovaBay reported 4Q16 revenue of 4M, inline with preannouncement back in January. Operating expenses were $6.1M up from the prior quarter's $5.5M. This translated into a net loss of $1.6M or $(0.11) per share. Novabay ended the quarter with $9.5M in cash or about $7M (est.) in cash today... We have adjusted our model to reflect the revenue guidance. We conclude that without a revenue breakout, (driven by additional capital), our model suggests a target valuation in the current range. As such, we maintain our Hold rating." (3/24/2017)

Who are some of NovaBay Pharmaceuticals' key competitors?

Who are NovaBay Pharmaceuticals' key executives?

NovaBay Pharmaceuticals' management team includes the folowing people:

  • Mark M. Sieczkarek, Interim Chairman of the Board, President, Chief Executive Officer (Age 61)
  • John Joseph McGovern, Chief Financial Officer, Treasurer (Age 60)
  • Justin M. Hall Esq., Senior Vice President, General Counsel (Age 38)
  • Lewis J. Stuart, Chief Commercial Officer (Age 58)
  • Xinzhou Li, Director (Age 52)
  • Xiaoyan Liu, Director (Age 42)
  • Yonghao Ma Ph.D., Director
  • Mijia Wu, Director (Age 42)
  • Todd E. Zavodnick, Director (Age 45)

How do I buy NovaBay Pharmaceuticals stock?

Shares of NovaBay Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NovaBay Pharmaceuticals' stock price today?

One share of NovaBay Pharmaceuticals stock can currently be purchased for approximately $3.45.

How big of a company is NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals has a market capitalization of $54.92 million.

How can I contact NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800.


MarketBeat Community Rating for NovaBay Pharmaceuticals (NBY)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  86 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  172
MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.802.802.80
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.33$6.25$6.25$7.00
Price Target Upside: 42.32% upside40.45% upside40.45% upside47.37% upside

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Consensus Price Target History

Price Target History for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/15/2017LaidlawLower Price TargetBuy -> Buy$10.00 -> $8.00View Rating Details
11/15/2017HC WainwrightSet Price TargetBuy$6.00View Rating Details
10/23/2017Roth CapitalSet Price TargetBuy$5.00View Rating Details
8/11/2017Maxim GroupReiterated RatingHoldView Rating Details
2/6/2017Rodman & RenshawInitiated CoverageBuy$6.00View Rating Details
(Data available from 2/22/2016 forward)

Earnings

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Earnings History and Estimates Chart

Earnings by Quarter for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals (NYSEAMERICAN NBY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3($0.07)($0.16)$4.69 million$4.09 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.12)($0.11)$4.57 million$4.12 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.14)($0.26)$4.08 million$3.70 millionViewN/AView Earnings Details
3/23/2017Q4 2016($0.12)($0.13)$4.03 million$4.08 millionViewN/AView Earnings Details
11/10/2016Q316($0.16)($0.34)$3.02 million$3.40 millionViewN/AView Earnings Details
8/11/2016Q216($0.30)($0.36)$1.76 million$2.70 millionViewListenView Earnings Details
5/12/2016Q116($0.68)($1.24)$1.84 million$1.70 millionViewListenView Earnings Details
3/3/2016Q415($1.36)($1.26)$1.43 million$1.60 millionViewN/AView Earnings Details
11/19/2015Q315($0.07)($0.07)$1.06 million$1.20 millionViewListenView Earnings Details
8/13/2015Q215($0.07)($0.07)$610.00 million$1.01 millionViewListenView Earnings Details
5/14/2015Q1($0.06)($0.09)$0.54 millionViewN/AView Earnings Details
3/26/2015Q414($0.07)($0.09)$0.49 millionViewN/AView Earnings Details
11/12/2014Q314($0.09)($0.08)$0.15 millionViewN/AView Earnings Details
7/31/2014($0.09)($0.06)$0.12 millionViewN/AView Earnings Details
5/1/2014Q114($0.11)($0.08)$0.19 millionViewN/AView Earnings Details
3/7/2014Q4 2013$2.50$0.37 millionViewN/AView Earnings Details
11/12/2013Q3($0.10)$1.10 millionViewN/AView Earnings Details
8/1/2013Q2 2013($2.75)$0.85 millionViewN/AView Earnings Details
5/2/2013Q113($0.07)($0.11)$1.18 million$0.96 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.09)($0.08)$1.50 millionViewN/AView Earnings Details
8/9/2012Q2 2012($2.00)($1.95)ViewN/AView Earnings Details
5/3/2012Q1 2012($1.75)($2.23)ViewN/AView Earnings Details
3/27/2012Q4 2011($2.30)ViewN/AView Earnings Details
11/7/2011Q3 2011($1.75)($0.30)ViewN/AView Earnings Details
8/10/2011Q2 2011($2.00)$0.45ViewN/AView Earnings Details
5/16/2011Q1 2011($2.00)ViewN/AView Earnings Details
3/10/2011Q4 2010($2.00)$0.18ViewN/AView Earnings Details
11/12/2010Q3 2010($1.75)($1.75)ViewN/AView Earnings Details
8/12/2010Q2 2010($1.75)($1.28)ViewN/AView Earnings Details
5/12/2010Q1 2010($2.00)($1.75)ViewN/AView Earnings Details
3/30/2010Q4 2009($0.50)$3.58ViewN/AView Earnings Details
11/13/2009Q3 2009($0.25)($0.13)ViewN/AView Earnings Details
8/14/2009Q2 2009($2.50)($0.33)ViewN/AView Earnings Details
5/18/2009Q1 2009($1.25)($0.38)ViewN/AView Earnings Details
4/1/2009Q4 2008($2.50)($1.75)ViewN/AView Earnings Details
11/14/2008Q3 2008($3.75)($1.73)ViewN/AView Earnings Details
8/14/2008Q2 2008($3.25)($2.83)ViewN/AView Earnings Details
5/14/2008Q1 2008($3.15)ViewN/AView Earnings Details
3/11/2008Q4 2007($2.13)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

NovaBay Pharmaceuticals (NYSEAMERICAN NBY) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals (NYSEAMERICAN NBY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/25/2017Jacques BonneauDirectorBuy25,000$0.22$5,500.00
10/18/2017Jacques BonneauDirectorBuy50,000$0.16$8,000.00
9/8/2017Jean-Sébastien DavidDirectorBuy12,300$0.20$2,460.00
9/7/2017Jean-Sébastien DavidDirectorBuy15,000$0.20$3,000.00
9/6/2017Claude DufresneDirectorBuy10,000$0.21$2,100.00
8/21/2017Claude DufresneDirectorBuy10,000$0.13$1,300.00
6/26/2017Serge SavardDirectorBuy52,000$0.18$9,360.00
6/23/2017Serge SavardDirectorBuy10,000$0.17$1,700.00
6/21/2017Serge SavardDirectorBuy18,500$0.17$3,145.00
6/20/2017Serge SavardDirectorBuy101,000$0.17$17,170.00
6/19/2017Serge SavardDirectorBuy18,500$0.17$3,145.00
4/26/2017Claude DufresneDirectorBuy2,000$0.76$1,520.00
3/6/2017Jean-Sébastien DavidDirectorBuy3,820$0.81$3,094.20
1/12/2017Claude DufresneDirectorSell21,000$0.77$16,170.00
8/20/2015Ramin NajafiCEOBuy12,000$0.47$5,640.00View SEC Filing  
3/3/2015Pharma (Singapore) Pte PioneerMajor ShareholderBuy2,590,000$0.60$1,554,000.00View SEC Filing  
3/3/2015Ramin NajafiChairmanBuy166,666$0.60$99,999.60View SEC Filing  
12/12/2014Ramin NajafiChairmanBuy50,000$0.65$32,500.00View SEC Filing  
12/12/2014Thomas J PaulsonCFOBuy10,000$0.68$6,800.00View SEC Filing  
12/11/2014Ramin NajafiChairmanBuy20,000$0.60$12,000.00View SEC Filing  
12/9/2014Thomas J PaulsonCFOBuy10,000$0.67$6,700.00View SEC Filing  
12/5/2014Ramin NajafiChairmanBuy25,000$0.65$16,250.00View SEC Filing  
12/2/2014Ramin NajafiChairmanBuy18,000$0.71$12,780.00View SEC Filing  
12/2/2014Tony D.S. WicksDirectorSell20,000$0.70$14,000.00View SEC Filing  
6/4/2014Mark M SieczkarekDirectorBuy4,800$0.89$4,272.00View SEC Filing  
5/19/2014Mark M SieczkarekDirectorBuy25,000$0.88$22,000.00View SEC Filing  
5/13/2014Pioneer Pharma Holdings ChinaMajor ShareholderBuy65,065$0.99$64,414.35View SEC Filing  
5/12/2014Pioneer Pharma Holdings ChinaMajor ShareholderBuy116,107$0.99$114,945.93View SEC Filing  
5/9/2014Pioneer Pharma Holdings ChinaMajor ShareholderBuy318,828$0.99$315,639.72View SEC Filing  
12/2/2013Pioneer Pharma Holdings ChinaMajor ShareholderBuy5,000,000$1.14$5,700,000.00View SEC Filing  
12/11/2012Xinzhou LiInsiderBuy120,000$1.20$144,000.00View SEC Filing  
12/6/2012Ramin NajafiChairmanBuy20,000$1.24$24,800.00View SEC Filing  
12/6/2012Thomas J PaulsonCFOBuy10,000$1.24$12,400.00View SEC Filing  
10/31/2012Area Pioneer Pharma Co. NaquMajor ShareholderBuy1,200,000$1.25$1,500,000.00View SEC Filing  
9/13/2012Xinzhou LiMajor ShareholderBuy800,000$1.25$1,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

NovaBay Pharmaceuticals (NYSEAMERICAN NBY) News Headlines

Source:
DateHeadline
NovaBay Pharmaceuticals to Hold 2017 Fourth Quarter and Full Year Conference Call on March 20, 2018NovaBay Pharmaceuticals to Hold 2017 Fourth Quarter and Full Year Conference Call on March 20, 2018
finance.yahoo.com - February 21 at 9:52 AM
NovaBay Pharmaceuticals (NBY) Raised to Hold at Zacks Investment ResearchNovaBay Pharmaceuticals (NBY) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - February 15 at 6:26 AM
Your Daily Pharma Scoop: Akebia Update, Rexahn Data, Concert Commences EnrollmentYour Daily Pharma Scoop: Akebia Update, Rexahn Data, Concert Commences Enrollment
seekingalpha.com - February 14 at 9:01 AM
NovaBay Pharmaceuticals Completes $6.0 Million Private PlacementNovaBay Pharmaceuticals Completes $6.0 Million Private Placement
finance.yahoo.com - February 12 at 8:57 AM
NovaBay Pharmaceuticals, Inc. (NBY) Given Average Rating of "Hold" by AnalystsNovaBay Pharmaceuticals, Inc. (NBY) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - February 10 at 1:48 AM
NovaBay Pharmaceuticals (NBY) Downgraded to Sell at Zacks Investment ResearchNovaBay Pharmaceuticals (NBY) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - February 9 at 12:06 PM
NovaBay Pharma (NBY) Enters Share Purchase Agreement for Sale of 1,700,000 Shares of Common StockNovaBay Pharma (NBY) Enters Share Purchase Agreement for Sale of 1,700,000 Shares of Common Stock
www.streetinsider.com - February 6 at 4:33 PM
NovaBay Pharmaceuticals, Inc. (NBY) Receives Consensus Rating of "Hold" from AnalystsNovaBay Pharmaceuticals, Inc. (NBY) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 16 at 2:04 AM
NovaBay Pharmaceuticals, Inc. (NBY) Short Interest Up 32.1% in DecemberNovaBay Pharmaceuticals, Inc. (NBY) Short Interest Up 32.1% in December
www.americanbankingnews.com - January 10 at 6:06 PM
NovaBay Pharmaceuticals Announces Preliminary Sales for 2017 Fourth Quarter and Full YearNovaBay Pharmaceuticals Announces Preliminary Sales for 2017 Fourth Quarter and Full Year
finance.yahoo.com - January 8 at 8:04 AM
NovaBay Pharmaceuticals Gets Stockholder Approval for Proposed $10.32 Mln Financing DealNovaBay Pharmaceuticals Gets Stockholder Approval for Proposed $10.32 Mln Financing Deal
www.nasdaq.com - December 22 at 9:17 AM
NovaBay Pharmaceuticals Receives Stockholder Approval for Proposed $10.32 Million Financing AgreementNovaBay Pharmaceuticals Receives Stockholder Approval for Proposed $10.32 Million Financing Agreement
finance.yahoo.com - December 22 at 9:17 AM
NovaBay Pharmaceuticals, Inc. (NBY) Given Average Rating of "Hold" by BrokeragesNovaBay Pharmaceuticals, Inc. (NBY) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 22 at 2:06 AM
NovaBay Pharmaceuticals Regains Compliance with NYSE American Continued Listing StandardsNovaBay Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
finance.yahoo.com - December 21 at 9:07 AM
ETFs with exposure to NovaBay Pharmaceuticals, Inc. : December 19, 2017ETFs with exposure to NovaBay Pharmaceuticals, Inc. : December 19, 2017
finance.yahoo.com - December 19 at 5:20 PM
NovaBay Pharma (NBY) Names Lewis Stuart CCONovaBay Pharma (NBY) Names Lewis Stuart CCO
www.streetinsider.com - December 6 at 5:39 PM
ETFs with exposure to NovaBay Pharmaceuticals, Inc. : November 30, 2017ETFs with exposure to NovaBay Pharmaceuticals, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 5:18 PM
NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 9:09 AM
NovaBay Pharmaceuticals, Inc. (NBY) Given Consensus Recommendation of "Hold" by BrokeragesNovaBay Pharmaceuticals, Inc. (NBY) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 27 at 2:06 AM
HC Wainwright Analysts Give NovaBay Pharmaceuticals, Inc. (NBY) a $6.00 Price TargetHC Wainwright Analysts Give NovaBay Pharmaceuticals, Inc. (NBY) a $6.00 Price Target
www.americanbankingnews.com - November 19 at 5:38 PM
Laidlaw Trims NovaBay Pharmaceuticals, Inc. (NBY) Target Price to $8.00Laidlaw Trims NovaBay Pharmaceuticals, Inc. (NBY) Target Price to $8.00
www.americanbankingnews.com - November 19 at 11:14 AM
NovaBay Pharmaceuticals, Inc. (NBY) Posts Quarterly  Earnings Results, Misses Estimates By $0.09 EPSNovaBay Pharmaceuticals, Inc. (NBY) Posts Quarterly Earnings Results, Misses Estimates By $0.09 EPS
www.americanbankingnews.com - November 15 at 1:05 PM
NovaBay Pharmaceuticals, Inc. (NBY) Price Target Cut to $8.00NovaBay Pharmaceuticals, Inc. (NBY) Price Target Cut to $8.00
www.americanbankingnews.com - November 15 at 8:28 AM
NovaBay Pharmaceuticals (NBY) CEO Mark Sieczkarek on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaNovaBay Pharmaceuticals (NBY) CEO Mark Sieczkarek on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 15 at 6:40 AM
BRIEF-Jinzi Hams unit to invest in Novabay Pharma and become its biggest shareholderBRIEF-Jinzi Ham's unit to invest in Novabay Pharma and become its biggest shareholder
finance.yahoo.com - November 15 at 6:40 AM
NovaBay Pharmaceuticals, Inc. to Host Earnings CallNovaBay Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 15 at 6:40 AM
NovaBay Pharmaceuticals Reports Third Quarter 2017 Financial ResultsNovaBay Pharmaceuticals Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 15 at 6:40 AM

SEC Filings

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

NovaBay Pharmaceuticals (NYSEAMERICAN NBY) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.